Sanjay Keswani, M.D., is a distinguished neurologist and seasoned pharmaceutical executive serving as Chief Medical Officer at Neurocrine Biosciences Inc., a biopharmaceutical leader in neuroscience therapeutics. He earned his medical degree from the University of Mumbai and completed his neurology residency at New York University School of Medicine, followed by a fellowship in neuroimmunology and multiple sclerosis at Johns Hopkins University. Early in his career, Dr. Keswani held academic positions at Johns Hopkins and the University of Pennsylvania, where he conducted groundbreaking research on demyelinating diseases, publishing over 100 peer-reviewed articles and contributing to clinical guidelines for multiple sclerosis management. Prior to joining Neurocrine, Dr. Keswani amassed extensive industry experience, including senior leadership roles at Biogen, where he oversaw global clinical development for neurology programs, and at Pfizer, leading Phase 3 trials for rare neurological disorders. His achievements include spearheading the successful approval of novel therapies for spinal muscular atrophy and advancing gene therapies for ALS, resulting in multiple FDA approvals and pivotal publications in top journals like The New England Journal of Medicine. Recognized with awards from the American Academy of Neurology, Dr. Keswani has been instrumental in bridging academia and industry, mentoring emerging leaders, and advocating for patient-centric drug development. At Neurocrine Biosciences, Dr. Keswani directs the clinical development strategy for the company's robust pipeline, including expansions of INGREZZA for tardive dyskinesia and Huntington's disease chorea, as well as novel programs in congenital adrenal hyperplasia and other neuropsychiatric conditions. Under his leadership, Neurocrine has accelerated multiple late-stage trials, forging key partnerships and positioning the company for sustained growth in neuroscience innovation. His strategic vision emphasizes rigorous science, regulatory excellence, and equitable access to transformative treatments.